Bausch Health (BHC) Companies announced the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. Most recently, at Bristol-Meyers Squibb, he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles including Senior Vice President and Global Programs Head for Immunology, Cardiovascular and Neuroscience, Immunology Therapeutic Area Head, as well as the China R&D Head. In his new role, Jonathan will be responsible for overseeing the entire R&D process, working closely with our scientists and engineers. He will set the strategic direction and ensure alignment with our overall goal of enriching lives through our relentless drive to deliver better health outcomes.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Bristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy
- Bristol Myers receives positive CHMP opinion for repotrectinib
- Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story
- Bristol Myers initiated with a Peer Perform at Wolfe Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
